Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy
Trial ID or NCT#
NCT02464228
Status
NOT RECRUITING
Purpose
Phase II study designed to investigate antitumor activity in terms of objective response rate (ORR) of tipifarnib subjects with advanced Peripheral T-Cell Lymphoma (PTCL). Tipifarnib will be administered orally until disease progression.
Official Title
An Open Label Phase II Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma
Investigator(s)
Ranjana Advani
Lymphoma specialist,
Hematologist-Oncologist
Saul A. Rosenberg, MD, Professor of Lymphoma
Lauren Maeda
Hematologist,
Lymphoma specialist,
Hematologist-Oncologist
Clinical Associate Professor, Medicine - Oncology
Contact us to find out if this trial is right for you.
Contact
Luu Q. Pham
650-736-6432
View on ClinicalTrials.gov
